Despite the clear improvements in clinical outcomes brought about by medical therapy with ß-blockers, ACE inhibitors and aldosterone antagonists, as well as by device therapy with cardiac resynchronisation, many patients with chronic heart failure (HF) remain symptomatic despite optimal medical therapy. Symptomatic HF can have devastating consequences for the quality of life of individuals, and impacts on their families as well as the wider community. HF represents a major socio-economic burden due to the huge number of individuals affected worldwide.
coronary occlusion performed in an exercise stress test 13 was found to reduce the occurrence of ventricular fibrillation from 100 % to 10 % (p<0.001).
14 The transition towards HF was provided by two large studies that demonstrated an inverse relationship between New York Heart Association (NYHA) class and BRS, with a higher mortality in HF patients with depressed BRS. 15 This predictive value of impaired vagal reflexes was present also among patients treated with ß-blockers. 16 When experimental studies on the effect of VS in animals with HF began to be published, [17] [18] [19] there was no reason to delay initiation of VS studies in man.
In constrast with the wide experience of VS in epilepsy, which is conducted through stimulation of the left vagus, the right vagus would be the natural choice for stimulation when targeting the heart itself. As one has to stimulate the intact vagus, the electrical Additional considerations are relevant. In HF there is an increased density of cardiac muscarinic receptors, likely to be secondary to reduced tonic vagal activity. 21 While postganglionic vagal nerve transmission seems to be intact in HF, pre-to post-ganglionic parasympathetic efferent neurotransmission via nicotinergic acetylcholine receptors seems to be impaired. 21 These nicotinergic receptors are agonist-dependent and chronic exposure to a nicotinic agonist during HF can re-establish efferent parasympathetic neural control of the sinus node. 22 These data enhance the pathophysiological rationale for the use of electrical preganglionic cervical vagal nerve stimulation to re-establish the diminished cardiac vagal tone in chronic HF.
Clinical Translation
Based on the experimental background and rationale, we moved into the clinical arena with a single centre study involving eight severely diseased patients, as appropriate for a non-traditional approach. This was the first-in-man study with chronic vagal stimulation for heart failure. 7 The encouraging preliminary results showed the technique to be safe and achievable, and possibly beneficial. It was logical to continue with a multicentre single-arm open-label interventional phase II study. 8 The pilot study enrolled 32 patients in total (94 % men; mean age 56 ± 11 years) with a history of chronic HF in symptomatic NYHA class II-IV and average left ventricular ejection fraction (LVEF) of 23 ± 8 %. The patients were on optimal medical therapy; and 19 had an implantable cardioverter-defibrillator (ICD).
These patients underwent implantation of the CardioFit 5000 system (BioControl Medical Ltd, Yehud, Israel), including; an implantable neurostimulator capable of delivering low-current electrical pulses (with adjustable parameters); a proprietary cuff with a bipolar electrode placed over the right vagus nerve; and an intracardiac sensing electrode placed in the right ventricle. This enables suppression of nerve stimulation when heart rate falls below a pre-determined value.
The stimulator is designed to sense the heart rate (via an intracardiac implanted electrode) and to deliver stimulation at preset delays from the R wave.
Function in Heart Failure (ANTHEM-HF) study. 25 Preliminary results from these two trials will be presented in September 2014.
Conclusion
It is evident that management of HF has entered a new phase of hope. As yet nobody can say whether or not the novel approach to modulate the autonomic nervous system by increasing vagal and decreasing cardiac-bound sympathetic activity will be successful.
However, there is undoubtedly merit in exploring this physiologicallybased attempt to improve the life of patients with heart failure. Within the next few years INOVATE-HF and the other ongoing studies will provide a clear answer. n
